The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000488303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
25/03/2026
Date registered
Help: Date registered
20/04/2026
Date last updated
Help: Date last updated
16/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
20/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A double-blind, placebo-controlled study to evaluate the safety, tolerability and potential antiseizure activity of adjunctive OV-329 therapy in adults with drug-resistant focal epilepsy.
Scientific title
A double-blind, placebo-controlled study to evaluate the safety, tolerability and potential antiseizure activity of adjunctive OV-329 therapy in adults with drug-resistant focal epilepsy.
Additional trial identifiers [1] 316865 0
None
Additional trial identifiers [2] 317937 0
OVID 329-26-001
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Epilepsy 341250 0
Condition category
Condition code
Neurological 337335 337335 0 0
Epilepsy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This phase II study aims to assess the safety, tolerability and pharmacokinetics of an investigational product -OV329 -as well as determining whether it reduces seizure frequency compared to baseline. OV329 will be administered orally once daily for 12 weeks followed by a 1 week taper period. For patients that are unable to tolerate the initial dose, a dose reduction will be possible.
Participants will be asked to bring their blister packs with them to each study visit and these will be checked by site staff to monitor compliance.
Intervention code [1] 333565 0
Treatment: Drugs
Description of the comparator or control
Placebo capsules will match the OV329 capsules for each dose strength. The capsules are composed of mannitol and magnesium stearate in a Hypromellose casing.
Control group
Placebo

Outcomes
Primary outcome [1] 344855 0
Assessment of Safety and tolerability as a composite outcome
Timepoint [1] 344855 0
Adverse events will be assessed at every visit. Physical exam and laboratory tests will be done before treatment, at 2, 4, 8 and 12 weeks. ECG tests will be done before treatment and at 4, 8 and 12 week visits. CSSRS will be completed prior to treatment and at the 12 week visit. Additionally, the 3 week post treatment taper follow up visit will include physical exams
Secondary outcome [1] 459536 0
Assessment of Antiseizure activity as a composite outcome
Timepoint [1] 459536 0
Seizure frequency will be recorded daily over a 4 week baseline period, 12 week maintenance treatment, 1 week treatment taper and 3 week follow up period.
Secondary outcome [2] 460615 0
Changes in Clinical Global Impression of Improvement
Timepoint [2] 460615 0
CGI questionnaires will be completed at baseline and then at 2, 4, 8 and 12 week visits.

Eligibility
Key inclusion criteria
1) Written informed consent
2) Male and female participants aged 18 to 65 years
3) Diagnosis of drug resistant focal epilepsy (in accordance with ILAE and additionally documented failure of 3 previous or current ASMs) for greater than or equal to 2 years and is having focal onset seizures despite having been treated in the past with more than or equal to 2 approved antiseizure medications
4) History of focal seizures at a frequency of greater than or equal to 4 countable seizures per 28 days and is unlikely to have a period of greater than or equal to 21 consecutive countable focal seizure free days.
5) Currently being treated and maintained with stable anti-seizure therapy and/or regimen of 1-3 ASMs for greater than or equal to 1 month prior to the screening visit,
6) Able and willing to maintain an accurate and complete daily written seizure diary
7) Willing and able to comply with the study procedures and visit schedules and must be able to follow verbal and written instructions.
8) Weighs at least 50 kg and body mass index (BMI) greater than or equal to 18.0 and less than 40.0 kg/m2 at screening.
9) Resting supine systolic blood pressure 90 to 145 mmHg and diastolic blood pressure no higher than 90 mmHg at Screening and Baseline
10) A 12-lead ECG with no clinically significant abnormalities and QTcF interval less than or equal to 450 milliseconds for males and less than or equal to 470 milliseconds for females at Screening and Baseline
11) Resting supine pulse rate between 45 and 100 beats per minute at Screening and Baseline.
12) Willing to abstain from illicit drugs, alcohol, use during study participation.
13) Willing to use contraception as specified in the protocol
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1) Previous exposure to OV329
2) Exposure to any investigational drug or device less than or equal to 30 days prior to screening or plans to take another investigational drug at any time during the study.
3) Time of onset of epilepsy treatment < 2 years prior to enrollment
4) Have generalized or combined focal and generalized epilepsy, or non-epileptic seizures within the last 12- month period prior to study entry.
5) Have fewer than 4 countable focal onset seizures in a 28-day period and/ or have greater than or equal to 21 consecutive seizure-free days during the prospective baseline period.
6) Have more than 100 total countable per 4-wk baseline period.
7) Current use of vigabatrin is not permitted
8) Seizures secondary to illicit drug or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or central nervous system (CNS) disease deemed progressive, metabolic illness or progressive degenerative disease.
9) Abnormal clinical laboratory test results at screening that suggest a clinically significant underlying disease that would compromise the well-being of the participant.
10) Uncontrolled diabetes, history of alcohol abuse within the last 2 years, active vitamin B12 or copper deficiency
11) History of cardiovascular or cerebrovascular disease, stroke or other uncontrolled serious medical illness, myocardial infarction within 6 months of baseline, congestive heart failure, history of long QT syndrome, a long QTcB or clinically significant laboratory abnormalities.
12) History or presence of gastritis, gastrointestinal tract, gastric bypass surgery, or hepatic disorder or other clinical condition which, in the opinion of the Investigator or designee, may affect the absorption, distribution, metabolism, or elimination of study drug. And, recent history of abnormal bowel movements, such as diarrhea, loose stools, or constipation, within 2 weeks prior to first dosing.
13) History or presence of drug abuse within the past 2 years prior to Screening visit.
14) History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
15) Use of dietary supplements or herbal preparations are not permitted if participant has not been using them consistently for < 6 months prior to screening or does not plan on remaining on stable doses during the study treatment period
16) Use of concomitant medications that are OAT inhibitors
17) A history of chronic noncompliance with drug regimens.
18) Plans to have any surgery during the screening and treatment or follow up periods.
19) Risk of suicide according to the Investigator’s clinical judgment or has made a suicide attempt in the previous 2 years prior to Screening visit. Participants should be excluded if they have had suicidal intent within the last 12 months
20) Pregnant or lactating

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The IXRS (central randomisation via computer/phone) will serve as the system of record for participant randomization and IP accountability. Study medication will be dispensed in accordance with the IXRS assignment and protocol procedures, without revealing treatment allocation.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
The IXRS will assign eligible participants to 2 treatment arms in a ratio of 1:1 according to the predefined randomization schedule.
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,WA,VIC
Recruitment outside Australia
Country [1] 27969 0
Israel
State/province [1] 27969 0
Country [2] 27970 0
Sweden
State/province [2] 27970 0
Country [3] 27971 0
Netherlands
State/province [3] 27971 0
Country [4] 27972 0
Belgium
State/province [4] 27972 0
Country [5] 27973 0
Spain
State/province [5] 27973 0
Country [6] 27974 0
Poland
State/province [6] 27974 0
Country [7] 27975 0
Korea, Republic Of
State/province [7] 27975 0
Country [8] 27976 0
China
State/province [8] 27976 0
Country [9] 28345 0
United Kingdom
State/province [9] 28345 0

Funding & Sponsors
Funding source category [1] 321465 0
Commercial sector/Industry
Name [1] 321465 0
Ovid Therapeutics Australia Pty Ltd
Country [1] 321465 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Ovid Therapeutics Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324216 0
None
Name [1] 324216 0
Address [1] 324216 0
Country [1] 324216 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319997 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319997 0
Ethics committee country [1] 319997 0
Australia
Date submitted for ethics approval [1] 319997 0
23/03/2026
Approval date [1] 319997 0
30/04/2026
Ethics approval number [1] 319997 0
Ethics committee name [2] 320964 0
Bellberry Human Research Ethics Committee D
Ethics committee address [2] 320964 0
Ethics committee country [2] 320964 0
Australia
Date submitted for ethics approval [2] 320964 0
20/05/2026
Approval date [2] 320964 0
10/07/2026
Ethics approval number [2] 320964 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149090 0
Prof Terence O'Brien
Address 149090 0
Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004
Country 149090 0
Australia
Phone 149090 0
+61 3 90762596
Fax 149090 0
Email 149090 0
Contact person for public queries
Name 149091 0
Matthew Jung
Address 149091 0
Ovid Therapeutics, 441 9th Avenue, NY, NY 10001
Country 149091 0
United States of America
Phone 149091 0
+16468754179
Fax 149091 0
Email 149091 0
Contact person for scientific queries
Name 149092 0
Julia Tsai, PhD
Address 149092 0
Ovid Therapeutics, 441 9th Avenue, NY, NY 10001
Country 149092 0
United States of America
Phone 149092 0
+12036231996
Fax 149092 0
Email 149092 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.